Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Commercial heat-treated concentrates were licensed in UK.

  • Read more about Commercial heat-treated concentrates were licensed in UK.

There was a meeting at Elstree of reference centre directors and others to devise treatment recommendations.

  • Read more about There was a meeting at Elstree of reference centre directors and others to devise treatment recommendations.

PFC issued heat-treated Factor 8 for routine use.

  • Read more about PFC issued heat-treated Factor 8 for routine use.

Reported at symposium in Groningen that heat treatment at 68°C for 24 hours inactivated HIV; PFC was heating its Factor 8 stocks; CBLA announced plans to heat all BPL Factor 8 by April 1985.

  • Read more about Reported at symposium in Groningen that heat treatment at 68°C for 24 hours inactivated HIV; PFC was heating its Factor 8 stocks; CBLA announced plans to heat all BPL Factor 8 by April 1985.

BPL started intensive development of what would become 8Y.

  • Read more about BPL started intensive development of what would become 8Y.

Haemophilia centres at Sheffield, St Thomas', Middlesex and Margate started to use heat-treated concentrates.

  • Read more about Haemophilia centres at Sheffield, St Thomas', Middlesex and Margate started to use heat-treated concentrates.

FDA licensed Armour's heat-treated product, followed by Alpha's and Cutter's products in February 1984.

  • Read more about FDA licensed Armour's heat-treated product, followed by Alpha's and Cutter's products in February 1984.

FDA licensed Hyland's dry heat-treated product.

  • Read more about FDA licensed Hyland's dry heat-treated product.

BPL started development work on a heat-treated 'Hepatitis-Safe' Factor 8 product.

  • Read more about BPL started development work on a heat-treated 'Hepatitis-Safe' Factor 8 product.

Alpha assessed it had the "nucleus of a process that needs about three or four months' work", and applied for a FDA licence for heat-treated product in January 1983.

  • Read more about Alpha assessed it had the "nucleus of a process that needs about three or four months' work", and applied for a FDA licence for heat-treated product in January 1983.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 808
  • Page 809
  • Page 810
  • Page 811
  • Current page 812
  • Page 813
  • Page 814
  • Page 815
  • Page 816
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.